GSEP
COGT icon

Golden State Equity Partners’s Cogent Biosciences COGT Stock Holding History

Golden State Equity Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-120
Closed -$4.62K – 600
2026
Q1 		$4.62K Buy
+120
New +$4.43K ﹤0.01% 1489

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Golden State Equity Partners's COGT Position: Q2 2026 in Review

Golden State Equity Partners sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 120 shares — an estimated $4.62K sold.

Golden State Equity Partners first reported a position in COGT in Q1 2026 and held it in 1 quarter. The position peaked at $4.62K in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Golden State Equity Partners reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 120 Cogent Biosciences shares in Q2 2026, an estimated $4.62K.
  • Golden State Equity Partners first reported a position in Cogent Biosciences in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Cogent Biosciences position peaked at $4.62K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.